비인강암의 치료 성적 및 예후 인자
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박우성 | - |
dc.contributor.author | 김선욱 | - |
dc.contributor.author | 지용배 | - |
dc.contributor.author | 송창면 | - |
dc.contributor.author | 박철원 | - |
dc.contributor.author | 태경 | - |
dc.date.accessioned | 2022-07-15T18:07:50Z | - |
dc.date.available | 2022-07-15T18:07:50Z | - |
dc.date.created | 2021-05-13 | - |
dc.date.issued | 2016-03 | - |
dc.identifier.issn | 2092-5859 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/154962 | - |
dc.description.abstract | Background and Objectives Nasopharyngeal carcinoma is an uncommon disease that is usually found in the advanced stage becuase its anatomical location makes early detection difficult. Radiation therapy or concurrent chemoradiation therapy is mainstay for treatment of nasopharyngeal carcinoma. We evaluated clinical characteristics and treatment outcomes of nasopharyngeal carcinoma and assessed prognostic factors related to survival. Subjects and Method We retrospectively reviewed medical records of 87 patients who were treated for nasopharyngeal carcinoma from 1994 to 2013. Clinical characteristics, pathologic type, stage, treatment modality, recurrence and survival were investigated. Results The mean follow-up period was 66.7 (12-232) months. Recurrence rates were not significantly different between the radiation therapy group and combined chemoradiation groups in the early stage (27.3% vs. 21.6%, p=0.644) and the advanced stage (21.4% vs. 31.3%, p=0.496). Five-year overall survival and disease free survival rate was 74.0% and 58.9%, respectively. Five-year overall survival rate of the combined chemoradiation therapy group was significantly lower than that of the radiation therapy group (64.4% vs. 94.1%, p=0.001). Distant metastasis was significantly correlated with survival in multivariate analysis. Conclusion In this study, the five-year overall survival rate was better in the radiation therapy group than in the combined chemoradiation group. This might be related to the fact that advanced stage disease was more common in the combined chemoradiation group. Further studies with larger study samples and longer follow-up are necessary to verify these results and determine optimal modalities for the treatment of nasopharyngeal carcinoma. Korean J Otorhinolaryngol-Head Neck Surg 2016;59(3):222-8 | - |
dc.language | 한국어 | - |
dc.language.iso | ko | - |
dc.publisher | 대한이비인후과학회 | - |
dc.title | 비인강암의 치료 성적 및 예후 인자 | - |
dc.title.alternative | Treatment Outcomes and Prognostic Factors of Nasopharyngeal Carcinoma | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | 지용배 | - |
dc.contributor.affiliatedAuthor | 송창면 | - |
dc.contributor.affiliatedAuthor | 태경 | - |
dc.identifier.doi | 10.3342/kjorl-hns.2016.59.3.222 | - |
dc.identifier.bibliographicCitation | 대한이비인후과학회지 두경부외과학, v.59, no.3, pp.222 - 228 | - |
dc.relation.isPartOf | 대한이비인후과학회지 두경부외과학 | - |
dc.citation.title | 대한이비인후과학회지 두경부외과학 | - |
dc.citation.volume | 59 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 222 | - |
dc.citation.endPage | 228 | - |
dc.type.rims | ART | - |
dc.identifier.kciid | ART002090464 | - |
dc.description.journalClass | 2 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordAuthor | Chemotherapy | - |
dc.subject.keywordAuthor | Concurrent chemoradiation | - |
dc.subject.keywordAuthor | Nasopharyngeal carcinoma | - |
dc.subject.keywordAuthor | Prognosis | - |
dc.subject.keywordAuthor | Radiation therapy. | - |
dc.identifier.url | https://www.kjorl.org/journal/view.php?doi=10.3342/kjorl-hns.2016.59.3.222 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.